Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report

Table 1 Randomized trials in metastatic bladder cancer

Regimen	No of patients	OR (%)	mOS (mo)	P value
MVAC	246	36	12.5	< 0.01
Cisplatin		11	8.2
MVAC	110	65	12.6	< 0.05
CISCA		46	10
MVAC	169	59	12.5	> 0.05
FAP		42	12.5
MVAC	263	58	14.1	> 0.05
HD-MVAC		72	5.5
MVAC	408	46	14.8	> 0.05
GC		50	13.8
MVAC	220	54	14.2	< 0.05
DC		37	9.3
MVAC	85	40	14.2	> 0.05
PC		28	13.8
GC	627	46	12.8	> 0.05
GCP		57	15.7

MVAC: Methotrexate, vinblastine, doxorubicin, and cisplatin; CISCA: Cyclophosphamide, cisplatin, and doxorubicin; FAP: 5-Fluorouracil, interferon-alpha-2b, and cisplatin; HD-MVAC: High-dose MVAC; GC: Gemcitabine and cisplatin; DC: Docetaxel and cisplatin; PC: Paclitaxel and carboplatin; GCP: Gemcitabine, cisplatin, and paclitaxel; OR: Overall response; mOS: Median overall survival.